Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3548341 | 0.92 | CYP1A2 (0.43) | CYP1A2SIGMAR1HPGDEPHX1 | |
| SCHEMBL3550788 | 0.92 | SIGMAR1 (0.45) | CYP1A2SIGMAR1EPHX1 | |
| SCHEMBL3547848 | 0.90 | SIGMAR1 (0.48) | CYP1A2SIGMAR1EPHX1 | |
| SCHEMBL3546443 | 0.90 | SIGMAR1 (0.48) | CYP1A2SIGMAR1EPHX1 | |
| SCHEMBL5703992 | 0.89 | PTGS1 (0.37) | PTGS1PTGS2 | |
| SCHEMBL1904180 | 0.83 | CHRM5 (0.32) | CHRM5ADRA2CCHRM2CHRM4CHRM1 | |
| SCHEMBL3542361 | 0.81 | PTGS1 (0.41) | PTGS1PTGS2 | |
| SCHEMBL17758775 | 0.80 | PTGS1 (0.41) | PTGS1PTGS2 | |
| SCHEMBL10771045 | 0.79 | PTGS1 (0.33) | PTGS1PTGS2 | |
| SCHEMBL21219899 | 0.79 | PTGS1 (0.33) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102471495-B | Aluminum chelate-based latent curing agent | SONY CHEM & INF DEVICE CORP | 2013-10-23 | — | — | CN | disclosed |
| CN-102471495-A | Aluminum chelate-based latent curing agent | SONY CHEM & INF DEVICE CORP | 2012-05-23 | — | — | CN | disclosed |
| US-7732627-B2 | High-purity cycloaliphatic diepoxy compound and preparation process thereof | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20080045729-A1 | High-Purity Cycloaliphatic Diepoxy Compound and Preparation Process Thereof | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2008-02-21 | — | — | US | disclosed |
| EP-1834949-A1 | HIGH-PURITY ALICYCLIC DIEPOXY COMPOUND AND PROCESS FOR PRODUCING THE SAME | Daicel Chemical Industries, Ltd. (JP) | 2007-09-19 | — | — | EP | disclosed |
| US-20070179256-A1 | High-purity alicyclic epoxy compound, process for production of the same, curable epoxy resin composition, cured product thereof, and application thereof | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1726588-A1 | HIGH-PURITY ALICYCLIC EPOXY COMPOUND, PROCESS FOR PRODUCING THE SAME, CURABLE EPOXY RESIN COMPOSITION, CURED ARTICLE THEREOF, AND USE | Daicel Chemical Industries, Ltd. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045729-A1 | High-Purity Cycloaliphatic Diepoxy Compound and Preparation Process Thereof | DUOX2, SQLE, HPD | CYP1A2 434/4885SIGMAR1 3854/4885HPGD 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.